Alexion Pharmaceuticals Inc


  • LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.

  • NEW YORK, June 26- U.S. healthcare companies are winning higher profit forecasts, bucking a wider trend on Wall Street, as pricey new biotech drugs hit the market and insurance enrollment rises under the Affordable Care Act.

  • June 2- Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain. The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.

  • *Hewlett-Packard's revenue misses Wall St estimates. Among momentum names, noted for high growth and perceptions of excessive valuation, Vertex Pharmaceuticals shares shot up 6 percent to $71.18, while Alexion Pharmaceuticals rose 2.5 percent to $160.48.

  • No respect! Market not rewarding good earnings Friday, 25 Apr 2014 | 10:28 AM ET
    A trader works on the floor of the New York Stock Exchange.

    This quarter's earnings have a clear trend: they either beat expectations or report in-line, which does little to help the stock.

  • UPDATE 1-Alexion Pharma raises 2014 profit forecast again Thursday, 24 Apr 2014 | 10:23 AM ET

    *Raises 2014 adj earnings forecast to $4.75- $4.85/ share. *1st- quarter adj earnings $1.53/ share vs est $1.26. The biotechnology company raised its full-year adjusted earnings forecast to $4.75- $4.85 per share from $4.37- $4.47.

  • April 24- Alexion Pharmaceuticals Inc reported stronger-than-expected adjusted net earnings due to robust sales of its sole product on the market, Soliris, and it raised its full-year profit forecast for the second time in less than two months.

  • US STOCKS-Wall St falls as momentum shares sink again Tuesday, 15 Apr 2014 | 1:23 PM ET

    NEW YORK, April 15- U.S. stocks fell on Tuesday as early gains evaporated when momentum shares once again lost ground, overshadowing a jump in Coca-Cola and Johnson& Johnson after their quarterly earnings. Tesla Motors Inc fell 5.5 percent to $187.25 and NetFlix Inc dropped 4.5 percent to $316.82 to rank among the worst performers in the Nasdaq 100 index.

  • Meet the poster child for momentum stock selloff Thursday, 10 Apr 2014 | 12:58 PM ET
    Traders work the floor of the New York Stock Exchange.

    This ETF has been the tip of the arrow when it comes to trading momentum stocks.

  • Midday movers: Apache, Hershey, Facebook & More Wednesday, 9 Apr 2014 | 12:18 PM ET

    Some of Wednesday's midday movers:

  • April 8- The last six weeks have been rough for investors who jumped into 2013' s big stock market winners like Netflix and Facebook, only to see their share prices crater. For now, they have shifted money to other parts of the equities market, instead of retreating to safe-havens like cash, and concerns that there will be a full-scale retreat are muted.

  • Gravity hits highflying tech stocks Monday, 7 Apr 2014 | 2:51 AM ET

    The tumble of once highflying tech stocks signals a potential shift in investors chasing eye-popping growth, the New York Times reports.

  • Wall St Week Ahead-Momentum names may see more pain Friday, 4 Apr 2014 | 9:04 PM ET

    Familiar names such as Netflix, Facebook and Tesla Motors, along with a number of biotechnology and cloud-computing stocks, have been pummeled in the last month. Facebook Inc, for example, has fallen nearly 22 percent from an intraday record reached less than a month ago.

  • Intuitive Surgical fell 5 percent to $513.42 while Alexion Pharmaceuticals slid 4 percent to $145.37. TripAdvisor Inc sank 5 percent to $86.75 and Netflix Inc shed 3.8 percent to trade at $341.39.

  • These three stocks are crushing the Nasdaq Monday, 24 Mar 2014 | 3:03 PM ET

    On a terrible day for the Nasdaq 100, a third of its decline can be pegged on three much-loved stocks.

  • $1,000 a pill? It's a US problem, pro says Monday, 24 Mar 2014 | 1:50 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.

  • *Gold drops on concerns about U.S. rate hike. *Slowing growth in Germany, China weighs on some investors. NEW YORK, March 24- Global equity markets fell on Monday, rattled by the ongoing Ukraine crisis and weak data from China, while gold fell on concerns about higher U.S. interest rates and a stronger dollar.

  • Midday movers: Tesla Motors, Netflix & Pandora Media Monday, 24 Mar 2014 | 12:18 PM ET
    People walk past a Tesla motor company dealership.

    Some of Tuesday's midday movers:

  • Clouds gather in markets; no storm forecast yet Wednesday, 12 Mar 2014 | 10:46 AM ET

    There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.

  • Midday movers: Facebook, MFC Industries, FMC & More Monday, 10 Mar 2014 | 12:56 PM ET
    Facebook's Paper mobile app

    Some of Monday's midday movers: